TEST FOR GENETIC SUSCEPTIBILITY TO BREAST AND OVARIAN CANCER
Genome Breast
What is the GenomeBreast study?
GenomeBreast is an innovative genetic test designed to identify the hereditary risk of developing breast and ovarian cancer by analyzing the BRCA1 and BRCA2 genes. These genes are known for their role in predisposition to these types of cancer, as mutations in them can significantly increase the risk of developing the disease. By utilizing next-generation sequencing, the test allows for an accurate and detailed analysis of these genes. The procedure is relatively simple: a small blood sample is taken and sent to the laboratory for analysis. The results are discussed with a medical specialist who can offer an individualized prevention and monitoring plan.
Why should we get tested?
The GenomeBreast genetic test is crucial for the early detection and prevention of breast and ovarian cancer. It provides information about genetic predispositions you may carry. This empowers you to take timely action to reduce your risk of developing the disease. Furthermore, early identification of potential genetic mutations can improve the chances of successful treatment and aid in making informed health decisions. The test also allows for informing close relatives who may share the same genetic risks, so they can also get tested in a timely manner.
What do we offer?
For years, MediKara has partnered with NMGenomix, a company that offers comprehensive genetic testing (including GenomeBreast), which includes consultation with a medical geneticist before and after the test. This approach ensures that clients fully understand the implications of their results and how to act upon them. Additionally, the test is performed using high-quality genetic analysis technologies, ensuring accuracy and reliability of the results. Furthermore, the company provides psychological support for clients who may need assistance in understanding and accepting their results.
Who should be examined?
The GenomeBreast test is especially recommended for women with a family history of breast or ovarian cancer, as well as for those diagnosed with cancer at a young age. It is also suitable for individuals with multiple relatives diagnosed with various types of cancer. This may indicate the presence of an inherited genetic syndrome. However, even without a clear family history, any woman can benefit from the test to be more informed about her health.
GenomeBreast provides information about: * **Genome data:** This includes DNA sequencing data, specifically related to cancer. * **Breast cancer research:** The platform focuses on research related to breast cancer, likely analyzing genomic data to understand its development, progression, and potential treatments. * **Specific genomic alterations:** It may detail mutations, copy number variations, or other genetic changes found in breast cancer samples. * **Clinical data:** Information about the patients from whom the samples were taken, such as their diagnosis, treatment response, and survival, might also be included. * **Bioinformatics resources:** Access to tools and databases for analyzing and visualizing genomic data.
GenomeBreast provides detailed information on the presence of mutations in the BRCA1 and BRCA2 genes. If such mutations are detected, this can indicate a significantly increased risk of developing breast or ovarian cancer. Based on the results, personalized monitoring and prevention plans can be developed. This includes prophylactic interventions, such as surgical removal of the breasts or ovaries, to significantly reduce risk. This information allows patients and their doctors to make informed decisions and take proactive health measures.
GenomeBreast is not just a test, but also a prevention tool. It enables a personalized approach to health and a long-term strategy for reducing cancer risk. For more information and details about the test, you can call tel. ☎️ 0878 500 730
